EUVIMEDEUVIMED entdecken
Open Access

Improved survival at the population level for patients with advanced Merkel cell carcinoma following availability of immunotherapy

Kelly G Paulson, Song Y Park, Shailender Bhatia, Daniel S Hippe, Paul Nghiem

Journal of the American Academy of Dermatology · 2025-07 · 93 (1) · 89-94

DOI: 10.1016/j.jaad.2025.03.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2025-07. Verfasst von Kelly G Paulson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Paul G. Allen Research Center, Providence-Swedish Cancer Institute, Seattle, Washington; Elson. S. Floyd College of Medicine, Washington State Univer…. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Skin Neoplasms, Immune Checkpoint Inhibitors, Immunotherapy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, University of Washington, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Merkel cell carcinoma (MCC) is an aggressive skin cancer with poor survival rates. Immune checkpoint inhibitors (ICIs) were Food and Drug Administration-approved for advanced MCC in 2017, but their real-world survival impact remains unclear. OBJECTIVE: Evaluate whether ICI introduction in the United States corresponded with improved survival. METHODS: This cohort study analyzed Surveillance, Epidemiology, and End Results data for MCC patients diagnosed from 2010 to 2021, grouped by 3-year periods, to calculate 2-year overall and relative survival. RESULTS: For 453 patients with metastatic MCC, 2-year relative survival improved from 23% (2010-2012) to 37% (2013-2015), 42% (2016-2018), and 54% (2019-2021) (P 2-fold increase in survival for advanced MCC patients at the population level, translating to ∼220 fewer deaths per year in the United States.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Merkel CellSkin NeoplasmsImmune Checkpoint InhibitorsImmunotherapyHumansMaleFemaleSEER ProgramAgedUnited StatesAged, 80 and overMiddle AgedSurvival RateAdultCohort Studies

Stichwörter der Autor:innen

Merkel cell carcinomaPD-(L)-1 inhibitorSEERimmune checkpoint inhibitorsimmunotherapyoverall survivalrelative survivalsurvival

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Paul G. Allen Research Center, Providence-Swedish Cancer Institute, Seattle, Washington; Elson. S. Floyd College of Medicine, Washington State University, Everett, Washington.
  • Fred Hutchinson Cancer Center, Seattle, Washington; University of Washington, Seattle, Washington.
  • Fred Hutchinson Cancer Center, Seattle, Washington; University of Washington, Seattle, Washington. Electronic address: pnghiem@uw.edu.

Förderung

  • NCI NIH HHS
  • University of Washington
  • NIH
  • Prostate Cancer Foundation
  • National Cancer Institute

Zitieren

APA

Paulson, K. G., Park, S. Y., Bhatia, S., Hippe, D. S., & Nghiem, P. (2025). Improved survival at the population level for patients with advanced Merkel cell carcinoma following availability of immunotherapy. Journal of the American Academy of Dermatology, 93(1), 89-94. https://doi.org/10.1016/j.jaad.2025.03.006

Vancouver

Paulson KG, Park SY, Bhatia S, Hippe DS, Nghiem P. Improved survival at the population level for patients with advanced Merkel cell carcinoma following availability of immunotherapy. Journal of the American Academy of Dermatology. 2025;93(1):89-94. doi:10.1016/j.jaad.2025.03.006

BibTeX
@article{Paulson2025,
  author = {Paulson, Kelly G and Park, Song Y and Bhatia, Shailender and Hippe, Daniel S and Nghiem, Paul},
  title = {Improved survival at the population level for patients with advanced Merkel cell carcinoma following availability of immunotherapy},
  journal = {Journal of the American Academy of Dermatology},
  year = {2025},
  volume = {93},
  number = {1},
  pages = {89--94},
  doi = {10.1016/j.jaad.2025.03.006}
}
Kostenlos starten →